Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492..
DOI: 10.3322/caac.21492
Wagner A.D., Syn N.L., Moehler M., Grothe W., Yong W.P., Tai B.C. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Dyst Rev. 2017;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4..
DOI: 10.1002/14651858.CD004064.pub4
Kitadai Y. Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer. Cancer Microenviron. 2010;3(1):109–116. doi: 10.1007/s12307-009-0032-9..
DOI: 10.1007/s12307-009-0032-9
Park D.J., Seo A.N., Yoon C., Ku G.Y., Coit D.G., Strong V.E. et al. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Ann Surg Oncol. 2015;22(3 Suppl.):S1508–S1515. doi: 10.1245/s10434-015-4790-y..
DOI: 10.1245/s10434-015-4790-y
Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M. et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858–863. doi: 10.1002/(SICI)10970142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A..
DOI: 10.1002/(SICI)10970142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A
Wilke H., Muro K., Van Cutsem E., Oh S.C., Bodoky G., Shimada Y. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235. doi: 10.1016/S1470-2045(14)70420-6..
DOI: 10.1016/S1470-2045(14)70420-6
Fuchs C.S., Tomasek J., Yong C.J., Dumitru F., Passalacqua R., Goswami C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–39. doi: 10.1016/S0140-6736(13)61719-5..
DOI: 10.1016/S0140-6736(13)61719-5
Al-Batran S.E., Hartmann J.T., Probst S., Schmalenberg H., Hollerbach S., Hofheinz R. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–1442. doi: 10.1200/JCO.2007.13.9378..
DOI: 10.1200/JCO.2007.13.9378
Ajani J.A., Fodor M.B., Tjulandin S.A., Moiseyenko V.M., Chao Y., Cabral Filho S. et al. Phase II multi‐institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23(24):5660–5667. doi: 10.1200/JCO.2005.17.376..
DOI: 10.1200/JCO.2005.17.376
Lorenzen S., Pauligk C., Homann N., Schmalenberg H., Jäger E., Al-Batran S.E. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013;108(3):519–526. doi: 10.1038/bjc.2012.588..
DOI: 10.1038/bjc.2012.588
Van Cutsem E., Boni C., Tabernero J., Massuti B., Middleton G., Dane F. et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015;26(1):149–156. doi: 10.1093/annonc/mdu496..
DOI: 10.1093/annonc/mdu496
Shah M.A., Janjigian Y.Y., Stoller R., Shibata S., Kemeny M., Krishnamurthi S. et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33(33):3874–3879. doi: 10.1200/JCO.2015.60.7465..
DOI: 10.1200/JCO.2015.60.7465
Guimbaud R., Louvet C., Ries P., Ychou M., Maillard E., André T. et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520–3526. doi: 10.1200/JCO.2013.54.1011..
DOI: 10.1200/JCO.2013.54.1011
Sym S.J., Ryu M.H., Lee J.L., Chang H.M., Kim T.W., Lee S.S. et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol. 2008;31(2):151–156. doi: 10.1097/COC.0b013e31815878a2..
DOI: 10.1097/COC.0b013e31815878a2
Thuss-Patience P.C., Kretzschmar A., Bichev D., Deist T., Hinke A., Breithaupt K. et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–2314. doi: 10.1016/j.ejca.2011.06.002..
DOI: 10.1016/j.ejca.2011.06.002
Klempner S.J., Maron S.B., Chase L., Lomnicki S., Wainberg Z.A., Catenacci D.V.T. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. Oncologist. 2019;24(4):475–482. doi: 10.1634/theoncologist.2018-0602..
DOI: 10.1634/theoncologist.2018-0602
Lorenzen S., Thuss-Patience P.C., Pauligk C., Goekkurt E., Ettrich T.J., Lordick F. et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: the RAMIRIS Study. J Clin Oncol. 2018;36(15S):4023. doi: 10.1200/JCO.2018.36.15_suppl.TPS4132..
DOI: 10.1200/JCO.2018.36.15_suppl.TPS4132
Vogl U.M., Vormittag L., Winkler T., Kafka A., Weiser-Jasch O., Heinrich B. et al. Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma – experience at two centres. J Gastrointest Oncol. 2020;11(2):366–375. doi: 10.21037/jgo.2020.03.10..
DOI: 10.21037/jgo.2020.03.10
Бесова Н.С., Титова Т.А., Артамонова Е.В., Строяковский Д.Л., Перминова Е.В., Юкальчук Д.Ю. и др. Переносимость рамуцирумаба во второй линии лечения больных диссеминированным раком желудка в рутинной клинической практике России. Медицинский совет. 2019;(19):104–113..
DOI: 10.21518/2079-701X-2019-19-104-113
Maugeri-Saccà M., Pizzuti L., Sergi D., Barba M., Belli F., Fattoruso S. et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res. 2013;32(1):67. doi: 10.1186/1756-9966-32-67..
DOI: 10.1186/1756-9966-32-67
Kim S.G., Oh S.Y., Kwon H.C., Lee S., Kim J.H., Kim S.H., Kim H.J. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol. 2007;37(10):744–749. doi: 10.1093/jjco/hym103..
DOI: 10.1093/jjco/hym103
Assersohn L., Brown G., Cunningham D., Ward C., Oates J., Waters J.S. et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol. 2004;15(1):64–69. doi: 10.1093/annonc/mdh007..
DOI: 10.1093/annonc/mdh007
Sym S.J., Hong J., Park J., Cho E.K., Lee J.H., Park Y.H. et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol. 2013;71(2):481–488. doi: 10.1007/s00280-012-2027-3..
DOI: 10.1007/s00280-012-2027-3
Gómez-Ulloa D., Amonkar M., Kothari S., Cheung W.Y., Chau I., Zalcberg J.R. et al. Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. BMC Gastroenterol. 2020;20(1):133. doi: 10.1186/s12876-020-01232-z..
DOI: 10.1186/s12876-020-01232-z
Бесова Н.С., Калинин А.Е., Неред С.Н., Трякин А.А., Гамаюнов С.В., Козлов Н.А. и др. Рак желудка: клинические рекомендации. 2020 г. Режим доступа: https://oncology-association.ru/files/clinical-guidelines-2020/Rak_zheludka.pdf.https://oncology-association.ru/files/clinical-guidelines-2020/Rak_zheludka.pdf
Бесова Н.С., Калинин А.Е., Неред С.Н., Трякин А.А., Гамаюнов С.В., Козлов Н.А. и др. Рак желудка: клинические рекомендации. 2020 г. Режим доступа: https://oncology-association.ru/files/clinical-guidelines-2020/Rak_zheludka.pdf.https://oncology-association.ru/files/clinical-guidelines-2020/Rak_zheludka.pdf
Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Coverno C., Das P. et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer. 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Coverno C., Das P. et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer. 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
Saavedra E., Hollebecque A., Soria J.C., Hartl D.M. Dysphonia induced by anti-angiogenic compounds. Invest New Drugs. 2014;32(4):774–782. doi: 10.1007/s10637-013-0049-2..
DOI: 10.1007/s10637-013-0049-2
Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–1795. doi: 10.1038/sj.bjc.6603813..
DOI: 10.1038/sj.bjc.6603813